A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

Active:	Yes
Cancer Type:	Ovarian Cancer	NCT ID:	NCT07023627
Trial Phases:	Phase II	Protocol IDs:	INCB123667-203 (primary) GOG-3129/INCB123667-203 ( Other Identifier ) (OTHE 2025-521513-14-00 ( Registry Identifier ) (REGISTR
Eligibility:	, Male and Female	Study Type:
Study Sponsor:	Incyte Corporation
NCI Full Details:	https://clinicaltrials.gov/study/NCT07023627

Summary

This study will evaluate the safety and efficacy of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer (PROC) With Cyclin E1 Overexpression.

Treatment Sites in Georgia

Northeast Georgia Medical Center - Gainesville
NGMC-Gainesville
Wisteria Building Suite 420
200 South Enota
Gainesville, GA 30501
770-219-8822
www.nghs.com

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.